GLSIClinical Trials•globenewswire•
Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team
Sentiment:Negative (35)
Summary
STAFFORD, Texas, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced its plan to build out its internal clinical trial management and operations team.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 19, 2025 by globenewswire